What investment strategy does Rosetta Capital focus on?

Rosetta Capital focuses on VC strategies in the private equity space.

How many portfolio companies does Rosetta Capital have?

Rosetta Capital has 16 active portfolio companies and 4 completed exits and 2 funds tracked on GP Intel.

Where is Rosetta Capital headquartered?

Rosetta Capital is headquartered in Haddenham, United Kingdom.

When was Rosetta Capital founded?

Rosetta Capital was founded in 2000.

What sectors does Rosetta Capital invest in?

Rosetta Capital invests across Healthcare.

What are Rosetta Capital's recent exits?

Recent realized exits by Rosetta Capital include: Inivata (2021) to NeoGenomics.

Home/GPs/Rosetta Capital

DetailCard

Rosetta Capital

Haddenham, United Kingdom·Founded 2000·

Venture Capital

·rosettacapital.com

Rosetta Capital Limited is a UK life-sciences and medical-device venture capital firm incorporated in 2000 (originally Bioscience Managers Limited) and headquartered in Haddenham, Buckinghamshire. Authorised and regulated by the Financial Conduct Authority (FRN 196844), it invests globally through direct secondary transactions, acquiring baskets of late-stage therapeutic, diagnostic and medical-device assets from venture funds, corporates and listed trusts seeking liquidity. Over 20-plus years the firm has completed 50-plus venture investments and currently manages Funds IV and V.

AUM

–

Funds

vintages 2013–2021

Portfolio

Exits

Rosetta Capital is a Haddenham venture capital firm with 16 active companies and 4 exits.

SectorsHealthcare

Key takeaways

·3 exits in the last 5 years · consistent DPI cadence.
·Average hold across 3 realized deals: 7 years.
·Top sector focus: Biotech (75% of portfolio).

Sector breakdown

20 companies

Biotech

15 · 75%

MedTech

3 · 15%

HealthTech

1 · 5%

Pharma

1 · 5%

Geography breakdown

3 geographies

Sweden

13 · 65%

6 · 30%

Ireland

1 · 5%

Key facts

HQHaddenham, United Kingdom

Founded2000

Employees6+

Websiterosettacapital.com

Recent exits

Rosetta Capital sold Inivata to NeoGenomics in 2021 after less than a year.

Rosetta Capital took Biosergen public in 2021 after 8 years.

Rosetta Capital took Modus Therapeutics public in 2021 after 8 years.

Rosetta Capital took Aprea Therapeutics public in 2019 after 6 years.

Coverage notes

2 funds tracked, 20 portfolio companies (16 active · 4 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund Rosetta Capital has raised, with its portfolio companies. Hand-checked from public filings.

2 funds

Fund

Strategy

Vintage

Size

Assets

Exits

Rosetta Capital V

Secondaries2021€57M6 assets1 exits

Secondaries

2021 · 5yr

€57M

Unrealized

6 held

Company	Entry
Carrick Therapeutics Biotech · Ireland	2021
Immunocore Biotech · UK	2021
Mereo BioPharma Biotech · UK	2021
Mission Therapeutics Biotech · UK	2021
PsiOxus Therapeutics Biotech · UK	2021
ReNeuron Biotech · UK	2021

Realized

1 exit

Company	Entry	Exit	Type	Buyer	MOIC
Inivata HealthTech · UK	2021	2021	Trade Sale	NeoGenomics	–

Rosetta Capital IV

Secondaries2013€30M10 assets3 exits

Secondaries

2013 · 13yr

€30M

Unrealized

10 held

Company	Entry
Akinion Pharmaceuticals Pharma · Sweden	2013
Axelar Biotech · Sweden	2013
Clanotech Biotech · Sweden	2013
Dilafor Biotech · Sweden	2013
Inhalation Sciences MedTech · Sweden	2013
NeoDynamics MedTech · Sweden	2013
NovaSAID Biotech · Sweden	2013
Pergamum Biotech · Sweden	2013
Promimic MedTech · Sweden	2013
Umecrine Mood Biotech · Sweden	2013

Realized

3 exits

Company	Entry	Exit	Type	Buyer	MOIC
Aprea Therapeutics Biotech · Sweden	2013	2019	IPO	–	–
Biosergen Biotech · Sweden	2013	2021	IPO	–	–
Modus Therapeutics Biotech · Sweden	2013	2021	IPO	–	–

About Rosetta Capital

Rosetta Capital is an alternative investment platform with capital deployed across 1 active fund vehicles, headquartered in London. The firm deploys capital across European mid and small-cap businesses spanning software, consumer, TMT, financials, healthcare and business services.

Investment thesis

The platform combines complementary investment strategies, deploying capital across software, consumer, TMT, financials, healthcare and business services businesses in the United Kingdom and broader European market. Multi-strategy capital deployment enables flexibility across the business lifecycle, with the partnership culture supporting management teams through growth, transmission and selective M&A across multiple fund vintages and asset classes.

Recent activity

Realised exits across the current platform vintages remain limited, with the portfolio in active deployment and value-creation phase. The platform tracks 1 dedicated investment vehicle, 15 active portfolio companies and 0 realised exits across the strategy's history.

Frequently asked questions

What investment strategy does Rosetta Capital focus on?: Rosetta Capital focuses on VC strategies in the private equity space.
How many portfolio companies does Rosetta Capital have?: Rosetta Capital has 16 active portfolio companies and 4 completed exits and 2 funds tracked on GP Intel.
Where is Rosetta Capital headquartered?: Rosetta Capital is headquartered in Haddenham, United Kingdom.
When was Rosetta Capital founded?: Rosetta Capital was founded in 2000.
What sectors does Rosetta Capital invest in?: Rosetta Capital invests across Healthcare.
What are Rosetta Capital's recent exits?: Recent realized exits by Rosetta Capital include: Inivata (2021) to NeoGenomics.